Trial Information

Summary: Open - Label Study of Alimta (pemetrexed) Combination with Cisplatin for Chemonaive Patients with Malignant Pleural Mesothelioma.

Study Description

The purpose of this protocol is to extend the clinical experience with ALIMTA plus Cisplatin in patients with malignant pleural mesothelioma.

Patient Inclusion:

• Histologically proven diagnosis of mesothelioma of the pleura
• Performance status of 70 or higher on the Karnofsky scale

Exclusion Criteria:

• You are excluded from this trial if you are a candidates for curative surgery
• You are excluded from this trial if you have received prior chemotherapy for mesothelioma
• You are excluded from this trial if you have received any investigational agent within 4 weeks before enrolling in this study.
• You are excluded from this trial if you have received radiation within previous 2 weeks.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:43:28 AM